• BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
FinanceTime
  • August 19th, 2026

FinanceTimeFinancetime

  • BUSINESS
    • FINANCE
    • LEGAL
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • HEALTHCARE & PHARMACEUTICALS
    • MEDIA & TELECOM
    • AEROSPACE AND DEFENSE
    • ENERGY
  • MARKETS
    • EUROPEAN MARKETS
    • ASIAN MARKETS
    • U.S. MARKETS
    • COMMODITIES
    • EMERGING MARKETS
    • DEALS
    • RATES & BONDS
  • WORLD
    • UNITED STATES
    • EUROPE
    • UNITED KINGDOM
    • ASIA PACIFIC
    • MIDDLE EAST
    • AFRICA
    • CHINA
    • INDIA
    • JAPAN
    • AMERICAS
    • FRANCE
    • GERMANY
  • POLITICS
    • GOVERNMENT
    • UNITED STATES
    • US SUPREME COURT
  • TECH
    • ARTIFICIAL INTELLIGENCE
    • CYBERSECURITY
    • SPACE
    • DISRUPTED
  • COMMENTARY
  • BREAKINGVIEWS
    • BREAKINGVIEWS PREDICTIONS
  • MONEY
    • WEALTH
    • FUNDS
    • ETFS
  • LIFE
    • LIFESTYLE
    • SPORTS
    • SCIENCE
  • SECTORS
    • ENERGY
    • HEALTHCARE
    • MEDIA & TELECOM
    • SUSTAINABILITY
    • ENVIRONMENT
    • RETAIL & CONSUMER
    • AUTOS & TRANSPORTATION
    • AEROSPACE AND DEFENSE
People walk by a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. Andrew Kelly
People walk by a Walgreens, owned by the Walgreens Boots Alliance, Inc., in Manhattan, New York City, U.S., November 26, 2021. Andrew Kelly
Home
Litigation

Walgreens reaches $230 million opioid settlement with San Francisco

May 17th, 2023 | 18:29 PM Litigation 3

Facebook Twitter Google+ LinkedIn Pinterest

Worth reading...

Greater regulatory scrutiny no bar to mining mergers, bosses say
Moderna shares surge as melanoma vaccine with Merck succeeds in large trial
Former Meta engineer resumes testimony in landmark trial over social media's harm to young users
Novo begins study to find lowest effective dose for Wegovy pill
By Jonathan Stempel

San Francisco said on Wednesday it reached a $230 million settlement with Walgreens Boots Alliance Inc (WBA.O) over its role in the city's opioid epidemic.

The settlement came nine months after U.S. District Judge Charles Breyer in San Francisco said the drugstore chain could be held liable for having "substantially contributed" to an opioid epidemic that caused "widespread harm" in the city and constituted a public nuisance.

Breyer faulted Walgreens for its "15-year failure" to properly scrutinize opioid prescriptions and flag possible misuse of the sometimes highly addictive drugs.

At a press conference, San Francisco City Attorney David Chiu called Walgreens' settlement the largest awarded to a local government in years of opioid litigation nationwide.

He said Walgreens' actions "made the opioid epidemic in San Francisco worse than it otherwise would have been," and that there is "no amount of money that will bring back the lives we have lost."

In a statement, Walgreens said it "disputes liability" and did not admit fault, but that settling allows it to focus on patients, customers and communities. "Our thoughts are with those impacted by this tragic crisis," it added.

The Deerfield, Illinois-based company had been the only remaining defendant in San Francisco's civil lawsuit, after several drugmakers and distributors reached settlements worth more than $120 million.

In his ruling last Aug. 10, following a non-jury trial, Breyer found that Walgreens suffered from a profit-driven "fill, fill, fill" culture in dispensing opioids.

Breyer found that Walgreens' San Francisco pharmacies had received more than 1.2 million opioid prescriptions with "red flags" from 2006 to 2020, yet performed due diligence on less than 5% before dispensing them.

Walgreens' settlement averts a trial to determine damages.

San Francisco had estimated it might cost $8.1 billion to abate the opioid crisis, and that Walgreens was legally liable for the entire amount.

Last May, Walgreens reached a $683 million opioid settlement with Florida, paying more than three-quarters of the $878 million that four other companies, including rival CVS Health Corp (CVS.N), agreed to pay in similar, earlier settlements.

Opioids include legal painkillers such as OxyContin, and various forms of the drug fentanyl.

More than 600,000 people have died from drug overdoses in the United States from 1999 to 2021, including more than 107,000 in 2021 alone, according to the U.S. Centers for Disease Control and Prevention.

Walgreens shares closed up 69 cents at $32.04 in Wednesday trading on Nasdaq.

  • Topic
  • WALGREENS BOOTS
  • SAN FRANCISCO/OPIOIDS
  • SETTLEMENT (UPDATE 3, PIX)
Facebook Twitter Google+ LinkedIn Pinterest
Previous article Greater regulatory scrutiny no bar to mining mergers, bosses say

Related Posts

Litigation
August 19th, 2026

Greater regulatory scrutiny no bar to mining mergers, bosses say

Litigation
August 19th, 2026

Moderna shares surge as melanoma vaccine with Merck succeeds in large tr...

Litigation
August 19th, 2026

Former Meta engineer resumes testimony in landmark trial over social med...

Litigation
August 19th, 2026

Novo begins study to find lowest effective dose for Wegovy pill

Litigation
August 19th, 2026

Virgin Atlantic and Trainline under UK watchdog scrutiny over pricing

Litigation
August 19th, 2026

India court to rehear bankruptcy petitions against SpiceJet

The Wire
Aug 19th 4 h ago
Litigation

Greater regulatory scrutiny no bar to mining mergers, bosse...

Aug 19th 4 h ago
Energy

Turkey is ready to search for oil and gas in Syria, Turkish...

Aug 19th 4 h ago
Technology

Nebius plans $4.5 billion convertible debt sale to fund dat...

Aug 19th 4 h ago
Baseball

Now healthy, Blue Jays' Max Scherzer takes aim at Rays

Aug 19th 5 h ago
Retail & Consumer

Off-price retailer TJX raises annual profit forecasts

TRENDING ON FINANCETIME
Aug 19th, 2026 Business

European corporate outlook keeps improving as recovery goes beyond energy profits

Aug 19th, 2026 Baseball

With Jo Adell in question, Guardians chase series win vs. Giants

Aug 19th, 2026 Technology

Analog Devices' quarterly forecast tops estimates on AI-fueled chip demand

Aug 19th, 2026 India

Global shocks, IPO wave could temper India's earnings-led market revival, Abakkus Investment says

Aug 19th, 2026 Africa

Egypt to widen cash subsidy scheme to cover more essential foods

Markets-Sectors
HEALTHCARE +1.60%

  • BUSINESS
  • MARKETS
  • WORLD
  • POLITICS
  • TECH
  • COMMENTARY
  • BREAKINGVIEWS
  • MONEY
  • LIFE
  • SECTORS
  • Back to top
FinanceTime
FinanceTime

World Business & Financial News, Breaking US & International News

Additional Services
  • Privacy-Policy
  • Terms and Conditions
© Financetime.org 2026. All rights reserved. Hosted by LeadsDeposit.com
Produced by C-iT